PXT3003 Designated Promising Innovative Medicine in UK for CMT1A Treatment
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted promising innovative medicine (PIM) designation to PXT3003 for the treatment of people with Charcot-Marie-Tooth type 1A (CMT1A) aged 16 and older. PIM designation indicates that the MHRA considers PXT3003, an experimental oral therapy developed by Pharnext, likely to…